Chi-Med Completes Enrollment of Fruquintinib Phase III Trial in CRC

Hutchison China MediTech (Chi-Med) has fully enrolled a China Phase III trial of fruquintinib (HMPL-013) as a treatment for colorectal cancer. The trial enrolled 416 patients with locally advanced or metastatic disease who have previously received two previous rounds of treatment. Fruquintinib, which is also in a Phase III China trial for non-small cell lung cancer, targets VEGFR 1/2/3. Lilly in-licensed rights to the drug in 2013 in a deal worth $86 million plus royalties. More details.... Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY) Share this with colleagues: // //